Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07209930

Inter- and Intraindividual Variability of the Acute Glucose Response to Exercise in Healthy Adults and People Living With Type 1 Diabetes: A Cross-over Replicate Trial

The goal of this clinical trial is to investigate if blood glucose responses are similar between and within individuals in response to standardized exercise in adults with and without Type 1 diabetes. The main questions it aims to answer are:

What is the reproducibility of acute glycaemic responses to exercise within and between subjects in adults living with Type 1 Diabetes and in healthy adults? What is the agreement between glucose levels obtained by continuous glucose monitor (CGM) and blood glucose monitor?

Participants will cycle on a cycle ergometer or rest after consuming a standardized breakfast, while glucose levels are monitored by CGM and capillary blood sampling.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University College Dublin

Dublin, D04 V1W8, Ireland

Location status: Recruiting

Location contact

Veronica Merlo

CONTACT

[email protected]

3458479939 ext. +39

About this study

This study follows a non-blinded randomized replicate crossover study design. The study involves two phases, one phase will involve participants with T1D and the other phase will involve healthy adults. The sample size will be approximately 12 in each phase. Both phases will follow the same protocol consisting of 2 arms (exercise (EX) and rest).

Participants will attend 5 visits in total in the laboratory. They will first undergo baseline assessments and maximal exercise testing before being randomized to receive either an exercise (EX) or resting (REST) condition at their visit first. The two visits will then repeated to assess reproducibility of the outcomes in the same order the following week (EX RE and REST RE). All test visits will be separated by a minimum washout period of 72 hours.

The first visit will last approximately 1 hour and involves signing informed consent, body composition assessment (BodPod), maximal exercise testing (Vo2 max) and completion of questionnaires.

Before each condition, participants are asked to refrain from strenuous physical activity and alcohol for at least 24 hours prior to the test(s). Prior to the first main testing day (either EX or RE based on randomization), participants are asked to record their dietary intake for 24h and asked to replicate it in the same period before the subsequent conditions.

Testing visits have a duration of 2 hours each. Participants will arrive at the laboratory after an overnight fast always at the same time in the morning (about 9am). While seated, baseline measurements will be collected, including 2 blood glucose measurements via finger prick, 2 CGM measurements, RPE, HR, measures of heart rate variability (HRV), and participants will the intensity of any hypoglycaemia-related symptoms using a Visual Analogue Scale (VAS). The same measurements will be repeated at regular intervals throughout the visit.

Participants were then provided with a standardized breakfast meal (60g of CHO) that they were instructed to consume within 10 minutes. After consumption of the breakfast, a clock was started. Participants remained seated for 30 minutes, and - during the EX condition - cycled on a cycle ergometer for 30 minutes at an intensity equivalent to 10% above VT. Sixty minutes of rest sitting on a chair follow the 30-minute cycle, before participants can leave the laboratory.

The procedure for the resting condition visits is identical to that of the exercise condition, with the only difference being that the 30-minute cycling session is replaced by an additional 30 minutes of seated rest. This ensures that the total duration of the session and the timing of all measurements remains consistent across conditions.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

(Healthy and T1D phases):

  • age between 18 and 60 years old;
  • being healthy individuals;
  • engagement in physical activity at least once a week; (T1D phase):
  • diagnosis of T1D for >18 months;
  • hypoglycaemia self awareness.

Exclusion criteria

(Healthy and T1D phases)

  • presence of cardiovascular disease or contraindications to exercise;
  • infectious or inflammatory conditions;
  • chronic renal or liver disease;
  • pregnancy;
  • gestational diabetes;
  • diagnosed eating disorders;
  • any physical or mental condition preventing participation; (Healthy phase)
  • diabetes mellitus (type 1 or type 2); (T1D phase)
  • inability to self-manage diabetes.

Treatment and study plan

Exercise

Other

After a 12h overnight fast, baseline measurements are collected. Participants are then provided with a standardized breakfast meal (60g carbohydrate). After consumption of the breakfast, participants remain seated seated for 30 minutes, before cycling on a cycle ergometer for 30 minutes at an intensity equivalent to 10% above the first ventilatory threshold (VT1). Sixty minutes of rest sitting on a chair will follow the 30-minute cycle.

During the total 120 minute test, various measurements are collected at regular intervals, including: blood glucose measurements via finger prick, CGM measurements, RPE, HR, measures of heart rate variability (HRV) (RMSSD (Root Mean Square of Successive Differences) and SDNN (Standard Deviation of NN intervals)), and intensity of any hypoglycaemia-related symptoms using a Visual Analogue Scale (VAS).

Rest

Other

The procedure for the resting condition visits is identical to that of the exercise condition, with the only difference being that the 30-minute cycling session will be replaced by an additional 30 minutes of seated rest. This will ensure that the total duration of the session and the timing of all measurements will remain consistent across conditions.

Primary outcomes

  1. Interstitial glucose

    Time frame: Over 2 hours: 2 samples at baseline in the fasted state before breakfast consumption; and every 5 minutes following breakfast for 2 hours.

    Interstitial glucose values (mmol/l) collected via Freestyle libre 2 Continuous Glucose Monitor

  2. Capillary glucose

    Time frame: 2 hours: (1) at baseline before breakfast consumption; (2) every 10 minutes over 30 minutes after breakfast consumption during rest; (3) every 5 minutes for 30 minutes during cycle or seated rest based on intervention; (4) every 10 minutes for 60 min.

    Capillary glucose was measured via finger prick using a blood glucose monitor.

Secondary outcomes

  1. Heart-rate variability

    Time frame: 2 hours: (1) at baseline before breakfast consumption. (2) every 10 minutes for 120 minutes. (3) extra measurements of HR only were taken during the second thirty minutes, resulting in HR measurements at 5-minutes intervals during that time-frame.

    Measures of heart rate variability including HR, RMSSD and SSND were collected using polar monitors and chest straps.

  2. Perception of symptoms of Hypoglycaemia.

    Time frame: 2 hours: (1) at baseline before breakfast consumption; (2) every 20 minutes for 120 minutes.

    100 millimetre Visual Analogue Scales (VAS) will be used. This VAS has anchors located at each end of the scale. On the left end of the scale (0 mm), the "not at all" response is represented, while the right end (100 mm) represents the "extremely" response. Participants mark along the line where it most represents their subjective perception of 7 individual symptoms of hypoglycaemia (sweatiness; anxiety; hunger; thirst; difficulties in concentrating; blurred vision; dizziness) between both ends.

  3. Reporting of Perceived Exortion (RPE)

    Time frame: 1 hour: (1) at baseline before breakfast consumption; (2) every 5 minutes during the second half hour.

    Ratings of Perceived Exertion (RPE) were collected using the Borg 6-20 Scale. Participants were initially familiarised with the scale during their baseline visit to ensure proper understanding.

Study contacts

Contact information is provided by the study sponsor or research team.

Katy Horner

CONTACT

Veronica Merlo

CONTACT

[email protected]

3458479939 ext. +39

Sponsors and collaborators

Lead sponsor

University College Dublin

Other

Collaborators

  • Irish Research Council
  • Taighde Éireann - Research Ireland

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2026
First posted
Oct 7, 2025
Registry last updated
Oct 7, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.